Announced details
Strong inhibitory effects against all 14 types of BTK mutants, including mutants such as C481, T474 and L528W.
The company is conducting joint research with The University of Texas MD Anderson Cancer Center and Dr. Varsha Gandhi. Dr. Gandhi and colleagues participated as collaborators in the clinical trial of docirbrutinib, while Dr. Nitin Jain served as the principal investigator for this trial and a collaborator on the paper's research.
The University of Texas MD Anderson Cancer Center is a cancer center affiliated with The University of Texas. Dr. Varsha Gandhi is a professor in the center's Departments of Translational Molecular Pathology and Leukemia. Dr. Nitin Jain is a professor in the center's Department of Leukemia and the principal investigator for this clinical trial. Other information on location, capital and founding year is not disclosed.
DOI：10.1038/s41408-026-01509-8
United States (site of the Phase 1b trial)
No impact on financial results was disclosed.
The company does not address Contract Value / Offering price.
Blood Cancer Journal (published by Nature Publishing Group)
| Item | Details |
|---|---|
| Names of Products / Services Covered | docirbrutinib（AS-1763） |
| Counterparty | The University of Texas MD Anderson Cancer Center, Dr. Varsha Gandhi, Dr. Nitin Jain |
| Counterparty overview | The University of Texas MD Anderson Cancer Center is a cancer center affiliated with The University of Texas. Dr. Varsha Gandhi is a professor in the center's Departments of Translational Molecular Pathology and Leukemia. Dr. Nitin Jain is a professor in the center's Department of Leukemia and the principal investigator for this clinical trial. Other information on location, capital and founding year is not disclosed. |
| Relationship with the Company | The company is conducting joint research with The University of Texas MD Anderson Cancer Center and Dr. Varsha Gandhi. Dr. Gandhi and colleagues participated as collaborators in the clinical trial of docirbrutinib, while Dr. Nitin Jain served as the principal investigator for this trial and a collaborator on the paper's research. |
| Applicable area | Chronic lymphocytic leukemia (CLL), Small lymphocytic lymphoma (SLL), B-cell non-Hodgkin lymphoma (B-cell NHL) |
| Registration number and expiry date | DOI：10.1038/s41408-026-01509-8 |
| Location | United States (site of the Phase 1b trial) |
| Quantitative Effects | Strong inhibitory effects against all 14 types of BTK mutants, including mutants such as C481, T474 and L528W. |
| Impact on Business Performance | No impact on financial results was disclosed. |
| Source | Blood Cancer Journal (published by Nature Publishing Group) |
Items this document does not state (8)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because the paper was published online ahead of print in Blood Cancer Journal, published by Nature Publishing Group. The study evaluated the compound's activity against mutations conferring resistance to existing BTK inhibitors and the effects of combination treatment with venetoclax and AZD5991.